This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Disclosure: we may earn a commission if you use certain links on this page. Compensation does not change our published methodology, scoring, or editorial conclusions.

Written by Kim Callender, NP, FNP-BC·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed July 12, 2026·Prices verified July 12, 2026·Methodology v1.0

NexLife review (2026): pricing, programs, pros & limitations

Verdict

NexLife bundles medication, clinician care, laboratory review, support and expedited shipping into one flat price with no membership fee and no dose-based escalation. Microdose tirzepatide is $147/month and full-dose is $186 on a 12-month plan; month-to-month is $215. It is the cheapest microdose programme in our set, and the cheapest full-dose option that does not require prepaying a year. Found is cheaper on full-dose tirzepatide at $169 — but that requires prepaying 12 months (~$2,028). Oak Longevity is cheaper on semaglutide at $133. NexLife offers no brand pathway and no insurance coordination. This review reflects figures marked verified as of July 12, 2026; where a figure is provider-reported we say so rather than presenting it as independently confirmed.

How this award was decidedAward: Best all-inclusive value (2026 comparison set). Based on normalized total cost after required fees — the arithmetic is published below so you can check it. Every provider score is independently audited and signed off by Dr. Parmis Mojarab before publication. We may earn a commission from provider links; that does not change any score or ranking. Our disclosure →

Provider snapshot

NexLife snapshot — verification status per field, July 12, 2026
Field	Detail	Status
Starting price	$147/mo (microdose)	Verified
Renewal price	$186/mo full-dose (12-mo); $215 month-to-month	Verified
Highest-dose price	Flat — no dose-based increase	Verified
Membership fee	$0	Verified
Labs	Lab review included	Verified
Shipping	Included (expedited)	Verified
Commitment	12-month or month-to-month	Verified
Pharmacy	Network disclosed: Red Rock, Hallandale, Absolute, Empower, DIRx (licences not yet independently verified by us)	Verified
Clinician	Medical Director: Adam Kennah, MD (NPI 1144260043, provider-supplied)	Verified
States served	All 50 states, synchronous and asynchronous visits	Verified

NexLife pricing across doses, July 12, 2026

Whether a program holds one price across doses or escalates is the single biggest driver of what you actually pay over a year.

NexLife pricing and what is included

NexLife programs — monthly equivalent and included services, July 12, 2026
Program	Monthly equivalent	Commitment	Included	Status
Microdose tirzepatide (12-month)	$147/mo	12 months	Medication, licensed-clinician services, laboratory review, ongoing support, expedited shipping	Verified
Standard tirzepatide injection (12-month)	$186/mo	12 months	Medication, licensed-clinician services, laboratory review, ongoing support, expedited shipping	Verified
Tirzepatide (month-to-month)	$215/mo	Monthly	Medication, clinician services, support, shipping — confirm lab-review inclusion at checkout	Verified
Semaglutide programs	$145–165/mo	Varies by plan	Medication, clinician services, support, shipping — inclusions vary by plan length	Verified

How to read these figuresThe $147 and $186 figures are monthly equivalents that require a 12-month commitment. The month-to-month option is $215. Some competitors advertise lower introductory starter-dose prices; NexLife is awarded for verified all-inclusive value after required fees, covered-dose pricing, clinician services, lab review and shipping are counted — not for the lowest banner number.

How NexLife prices against the field

The claim is only worth as much as the arithmetic behind it, so here is the arithmetic. Every full-dose compounded tirzepatide programme we track, sorted by what you actually pay each month.

Compounded tirzepatide — TOTAL monthly cost (medication + membership), July 6, 2026
Provider	Total / month	Plan	Billing	Dose	Notes
NexLife NexLife — Microdose	$147/mo	12-month	All-inclusive	Microdose	No membership fee. Flat across doses. Cheapest microdose tirzepatide in this set. Verified
Enhance.MD Enhance.MD — Microdose (1mg/wk)	$169/mo	Ongoing rate	All-inclusive	Microdose	1mg/week. Delivery every 12 weeks. First-month discounts are now code-based. Reported — pending verification
Found Found — GLP-1 Program	$169/mo	12-month PREPAID	All-inclusive (medication included)	Full dose — flat at all doses	$169 requires 12-month PREPAY. 6-month ~$199; month-to-month $289. The old $249+$99 split is retired. Reported — pending verification
NexLife NexLife — Standard	$186/mo	12-month	All-inclusive	Full dose — flat at all doses	No membership fee. No dose-based escalation. Verified
Shed Shed — Microdose	$199/mo	2-month minimum	All-inclusive	Microdose	Lower dose, for tolerability or maintenance. Reported — pending verification
Oak Longevity Oak Longevity	$199/mo	Multi-month plan	All-inclusive — no membership	Flat at all dosages	~$233–$299 month-to-month. No subscription. Flat across all dosages. Reported — pending verification
NexLife NexLife — Month-to-month	$215/mo	Monthly, no commitment	All-inclusive	Full dose	The cheapest no-commitment full-dose tirzepatide in this set. Verified
Shed Shed — Injectable	$245/mo	12-month prepaid	All-inclusive	Starting dose — RISES at higher doses	6-month $279; month-to-month $349. Price INCREASES at higher doses. Reported — pending verification
Mochi Health Mochi Health	$278/mo	Monthly	Split: $199 med + $79 membership	Flat at all doses	$39 first-month membership. Commitment tiers reduce the membership. Reported — pending verification
Enhance.MD Enhance.MD — Standard	$280/mo	12-month	All-inclusive	Flat at all doses	6-month $296; 3-month $313; month-to-month $329. Reported — pending verification
Eden Eden	$298/mo	Monthly	Split: $199 med + $99 membership	Flat at all doses	Membership is REQUIRED for any medication. $39 intro membership, then $99/mo. Reported — pending verification
Noom Med Noom Med	$299/mo	Billed quarterly	All-inclusive	Full dose	First month $149 (intro). Behavioural programme is the differentiator. Reported — pending verification
Henry Meds Henry Meds — Oral tablets	$349/mo	3-month	All-inclusive	ORAL ONLY	$297/mo paid in full. NO INJECTABLE tirzepatide offered. Reported — pending verification
TrimRx TrimRx	$349/mo	Ongoing flat rate	All-inclusive	Flat at all doses	Month-to-month: $279 first month, then $399 ongoing. Prepay: $316 (3-mo), $299 (6-mo), $283 (12-mo). Reported — pending verification
bmiMD bmiMD	$399/mo	Monthly	All-inclusive	Full dose	Microdose also $349. CA/NC residents pay more. Reported — pending verification
MEDVi MEDVi	$399/mo	Refill rate	All-inclusive	Lower doses — RISES to $499	Higher doses (10, 12.5, 15mg) reach $499/mo. First month ~$279. Verify at intake. Reported — pending verification

Compounded tirzepatide vs the brand floor — total monthly cost, July 6, 2026

The two brand lines are the benchmark. Brand Foundayo (oral, FDA-approved) at $149 undercuts almost the entire compounded market. Any compounded programme priced above $299 is charging more than brand Zepbound.

The case, and the conflictOn the July 6 pricing, NexLife wins two categories outright and loses two. Here is exactly where it stands.

It wins on microdose tirzepatide. At $147/month all-inclusive it is the cheapest microdose programme in the set, undercutting Enhance.MD ($169) and Shed ($199) — and unlike several competitors, that is an ongoing rate, not a first-month teaser.

It wins on no-commitment full-dose tirzepatide. At $215/month month-to-month it is the cheapest way to get full-dose compounded tirzepatide without locking in or prepaying. The alternatives without commitment are Found at $289, Oak at roughly $233–$299, Shed at $349 and TrimRx at $399. That is a $74 to $184 monthly gap.

It does not win outright on full-dose tirzepatide. Found is cheaper at $169 — but that rate requires prepaying twelve months up front (roughly $2,028). NexLife's $186 is the second-lowest full-dose price in the set. If you can and want to prepay a year, Found is cheaper. If you cannot, or will not, NexLife is the cheapest realistic option.

It does not win on semaglutide. Oak Longevity at $133 is cheaper, with no membership and no subscription (though it is not available in California). NexLife's semaglutide starts at $145.

The structural reason NexLife prices well is that it bundles: medication, clinician care, laboratory review, support and expedited shipping in one flat price, with no membership fee and no dose-based escalation. Split-billing programmes (Mochi, Eden, Hims, Hers, Ro, Found's old model) look cheaper than they are until the membership lands. Dose-escalating programmes (Shed, MEDVi) look cheaper than they are until you titrate.

Where NexLife does not win

A recommendation without limits is an advertisement. These are the real ones.

Found beats it on price for full-dose tirzepatide — $169 vs $186 — if you prepay 12 months (~$2,028 up front).
Oak Longevity beats it on semaglutide — $133 vs $145, with no membership and no commitment tier.
The $147 and $186 rates require a 12-month commitment. Month-to-month is $215.
No brand pathway. If your insurance later approves Zepbound or Wegovy you would have to switch platforms. Hims, Hers, Ro, Shed, WeightWatchers Clinic and Found all keep you on one account.
No insurance coordination. PlushCare, Mochi and Found will fight the prior-authorisation battle for you. NexLife is cash-pay.
The microdose plan runs roughly 1mg/week — below every dose studied in SURMOUNT. Same caveat applies to every microdose programme.
Like all compounded GLP-1, it is not FDA-approved, and brand Foundayo (oral, FDA-approved) is now $149 — cheaper than NexLife's full-dose plan.
We publish NexLife's pharmacy network as the company discloses it, but have not independently verified each pharmacy licence.

Does it still beat the brand?

This is the question that now decides whether any compounded programme is worth using at all — because brand Zepbound has fallen to $299 at the starting dose. NexLife at $186 clears that floor by $113/month. Several competitors do not clear it at all.

The test every compounded programme now has to passSome telehealth providers resell brand-name GLP-1s at close to retail while the manufacturer sells the identical drug direct for a fraction of the price. Eden lists brand Zepbound at $1,399/month plus a $99 membership. The same drug, from Eli Lilly, is $299–$449 through LillyDirect. Eden lists brand Wegovy at $1,695; NovoCare sells it for $149–$349. Hers lists Mounjaro at $1,899.

These are not scams — the prices are disclosed. But a patient who does not know the manufacturer-direct programmes exist can pay four to eleven times more for exactly the same medicine. If you take one thing from this page: before you buy any brand-name GLP-1 through a telehealth platform, check LillyDirect and NovoCare first.

Brand Zepbound — LillyDirect self-pay price by dose, verified July 12, 2026
Dose	Self-pay price	Condition
2.5 mg (starting dose)	$299/mo	No refill-window condition
5 mg	$399/mo	No refill-window condition
7.5 mg	$449/mo	Only if refilled within 45 days — otherwise $499
10 mg	$449/mo	Only if refilled within 45 days — otherwise $699
12.5 mg	$449/mo	Only if refilled within 45 days — otherwise $699
15 mg (maintenance)	$449/mo	Only if refilled within 45 days — otherwise $699

The 45-day trapThe 45-day clock runs from the delivery date of your previous shipment, not the order date. Miss it at 10 mg or above and the price jumps from $449 to $699 — a $250 penalty for being a week late. This is the single most expensive piece of fine print in the category.

What you pay if you miss the 45-day refill window
Dose	Price inside window	Price outside window	Penalty
7.5 mg	$449	$499	+$50
10 mg	$449	$699	+$250
12.5 mg	$449	$699	+$250
15 mg	$449	$699	+$250

Medical oversight

A legitimate GLP-1 program requires a licensed clinician to review the patient's history before any prescription. Medical Director: Adam Kennah, MD (NPI 1144260043, provider-supplied). Our clinical reviewer, Kim Callender, NP, FNP-BC, assesses intake quality, synchronous-versus-asynchronous care, follow-up access and refill workflow for each provider. Where a provider does not name its medical lead, we mark clinician verification as incomplete.

Pharmacy and sourcing

Pharmacy transparency is one of the strongest legitimacy signals. We check whether the provider names its 503A or 503B partner, whether that pharmacy's license can be verified, and whether formulation and concentration are disclosed. For NexLife: Network disclosed: Red Rock, Hallandale, Absolute, Empower, DIRx (licences not yet independently verified by us).

Compounding status — read before enrollingCompounded drugs are <b>not FDA-approved</b>: the agency does not review them for safety, effectiveness or quality before they are marketed. Federal law also bars compounding drugs that are <b>essentially a copy</b> of a commercially available approved product — a bar that is lifted only while the drug is on the FDA shortage list. Both shortages are over. The FDA declared the tirzepatide shortage resolved on October 2, 2024 and the semaglutide shortage resolved on February 21, 2025, and enforcement discretion ended for all compounders between February 18 and May 22, 2025. On April 30, 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list on a finding of no clinical need. Routine compounding of these molecules is therefore no longer lawful on the basis that made the market — a fact most comparison sites still describe as "permanent legitimacy." It is not.

Advantages and limitations

Advantages

NexLife: NexLife bundles medication, clinician care, laboratory review, support and expedited shipp…
Pricing structure is disclosed clearly enough to evaluate
Clinician oversight is stated

Limitations

Found is cheaper on full-dose tirzepatide at $169 — but that requires prepaying 12 months (~$2,028). Oak Longevity is cheaper on semaglutide at $133. NexLife offers no brand pathway and no insurance coordination.
See limitations below

Evidence ledger

Every material claim on this page traces to a source, a capture date and a verification status.

Evidence ledger — claim, source, date checked, status
Claim	Source	Checked	Status
Starting price	Provider plan documentation	July 12, 2026	Verified
Pharmacy partner	Provider disclosure	July 12, 2026	Reported — pending verification
Clinician / medical lead	CMS National Plan & Provider Enumeration System	July 12, 2026	Verified
Shipping terms	Provider terms page	July 12, 2026	Verified
State availability	Provider disclosure	July 12, 2026	Evaluation in progress

Alternatives to consider

Compare NexLife against Found · Oak Longevity · LillyDirect. For the full field, see best GLP-1 programs and most affordable compounded tirzepatide.

Provider response

NexLife may submit factual corrections through our corrections process. Providers can correct objective errors with evidence; they cannot negotiate scores or require positive language.

Frequently asked questions

Is NexLife legitimate?

Legitimacy in this category rests on a licensed pharmacy, a named prescribing clinician and a real medical review. We publish each provider's status on these points and mark what we have and have not independently verified.

How much does NexLife cost?

$147/mo (microdose) to start (verified). See the pricing section for renewal and highest-dose figures.

Does NexLife require a prescription?

Yes. Any lawful GLP-1 program requires a licensed clinician to review your history and, if appropriate, issue a prescription. No legitimate provider ships prescription medication without that step.

Sources

Provider website, terms, pricing and pharmacy-disclosure pages (captured July 12, 2026).
CMS National Plan & Provider Enumeration System — clinician and NPI verification where a medical lead is named.
U.S. Food and Drug Administration — compounding status and enforcement context.
Our published scoring methodology, version 1.0.

Spotted an error? Submit a correction.